- Home
- TOUR vs ACRS Comparison
TOUR vs ACRS Comparison
Compare TOUR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOUR | ACRS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 868.5M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TOUR | ACRS |
|---|---|---|
| Price | $5.04 | $6.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 6.8K | ★ 1.6M |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $17.30 | N/A |
| Revenue Next Year | $14.00 | $4.24 |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.74 |
| 52 Week High | $7.79 | $6.60 |
Technical Indicators
Market Signals| Indicator | TOUR | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 48.86 |
| Support Level | $4.93 | $5.64 |
| Resistance Level | $5.32 | $6.56 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 49.20 | 26.23 |
Price Performance
Historical ComparisonAbout TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.